Paul Grayson is the founder of Tentarix Biotherapeutics. Tentarix Biotherapeutics has raised $132M in total funding. Latest round: Series B.
Paul Grayson is the President and CEO of Tentarix Biotherapeutics, a biotechnology company focused on leveraging its proprietary Tentacles™ platform to discover and develop multi-functional, conditional protein therapeutics. He has also been appointed as the CEO of Radionetics Oncology, a clinical-stage radiopharmaceutical company.
Full founder directory · Investor directory · Company funding database · Fundraising library